BRL-201 is under clinical development by BRL Medicine and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BRL-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BRL-201 is under development for the treatment of B-cell Lymphoma including relapsed and refractory non-Hodgkin lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma, follicular lymphoma and acute lymphocytic leukemia. It is administered through parenteral route. The therapeutic candidate comprises of PD1 knockout autologous T cells which are genetically modified to express chimeric antigen receptor that targets CD19.
For a complete picture of BRL-201’s drug-specific PTSR and LoA scores, buy the report here.